PROTAC AR Degrader-13

PROTAC AR Degrader-13 是一种靶向雄激素受体 (AR) 的蛋白降解嵌合体 (PROTACs),其在 LNCaP 细胞中 DC50 = 0.90 nM、hDPC 细胞中 DC50 = 0.23 nM,可诱导 AR 降解、下调 TGF-β1 表达、上调 β-catenin 水平并恢复毛囊内 Wnt/β-catenin 促增殖信号,在睾酮诱导雄激素性脱发小鼠模型中能加快毛发再生速率、提升毛发密度与毛发直径,可用于雄激素性脱发的研究。
PROTAC AR Degrader-13
产品编号: MS-B83307 分子式: C39H44ClF3N10O6 分子量: 841.28
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

PROTAC AR Degrader-13 是一种靶向雄激素受体 (AR) 的蛋白降解嵌合体 (PROTACs),其在 LNCaP 细胞中 DC50 = 0.90 nM、hDPC 细胞中 DC50 = 0.23 nM,可诱导 AR 降解、下调 TGF-β1 表达、上调 β-catenin 水平并恢复毛囊内 Wnt/β-catenin 促增殖信号,在睾酮诱导雄激素性脱发小鼠模型中能加快毛发再生速率、提升毛发密度与毛发直径,可用于雄激素性脱发的研究。

生物实验数据

生物活性 PROTAC AR Degrader-13 is a proteolysis-targeting chimera (PROTAC) targeting the androgen receptor (AR) with DC50 = 0.90 nM in LNCaP cells and DC50 = 0.23 nM in hDPC cells; it induces AR degradation, downregulates TGF-β1 expression, upregulates β-catenin levels, and restores Wnt/β-catenin pro-proliferative signaling within hair follicles, and in a testosterone-induced androgenetic alopecia mouse model it accelerates hair regeneration rate and increases hair density and hair diameter, making it useful for the study of androgenetic alopecia.
IC50 & Target

Cereblon

 

体外研究
(In Vitro)

PROTAC AR Degrader-13 (dAR-6-1) 可强效降解 LNCaP 细胞中的雄激素受体,其 DC50 为 0.90 nM,Dmax 为 91%。
PROTAC AR Degrader-13 (0.1-1000 nM; 0.5-36 h) 可强效降解人真皮乳头细胞 (hDPC) 中的雄激素受体,其 DC50 为 0.23 nM,Dmax 达 90%。
PROTAC AR Degrader-13 (0.1-500 μM; 72 h) 对人真皮乳头细胞 (hDPC) 的活力无显著抑制作用,处理 72 h 后的 IC50 > 500 μM。

Western Blot Analysis

Cell Line: human dermal papilla (hDPC) cells
Concentration: 0.1, 0.3, 1, 3, 10, 30, 100, 300, 1000 nM (6 h incubation)
10 nM (time-course incubations)
1, 10, 100 nM (4 h incubation with siRNA pretreatment)
1, 10, 100 nM (4 h incubation with inhibitor/ligand pretreatment)
Incubation Time: 6 h (0.1-1000 nM)
0.5, 1, 2, 3, 4, 6, 9, 12, 24, 36 h (10 nM)
4 h
Result: Induced rapid, sustained AR degradation, detectable within 2 h and maintained for over 36 h at 10 nM.
Exhibited dose-dependent degradation across 0.1-1000 nM without a hook effect, with a DC50 of 0.23 nM and a Dmax of 90%.
Abrogated degradation occurred with CRBN knockdown, while pretreatment with MG-132 (MS-L06849), Pevonedistat (MS-C57164), lenalidomide (MS-O60836), or enzalutamide (MS-H61960) blocked degradation.

Cell Viability Assay

Cell Line: hDPC cells
Concentration: 0.01, 0.1, 1, 10, 100, 1000 μM
Incubation Time: 72 h
Result: Did not induce significant growth inhibition, with cell viability remaining above ~90% at concentrations up to 100 μM, ~80% at 100−500 μM, and an IC50 > 500 μM.
体内研究
(In Vivo)

PROTAC AR Degrader-13 (dAR-6−1) (100 mg/mL;局部给药;每日 1 次;持续 28 天) 的局部应用在雄激素性脱发小鼠模型中诱导毛发再生的速度快于 Minoxidil (MS-Q24113),在第 28 天时毛发密度相当且毛发直径更大。
PROTAC AR Degrader-13 (1-100 mg/mL; topical) 在 C57BL/6 小鼠中经局部给药后,可产生浓度依赖性的皮肤滞留。

Animal Model: C57BL/6 (male, 6 weeks old, depilated on dorsal skin, treated daily with 0.5% testosterone solution to induce follicular miniaturization)
Dosage: 100 mg/mL
Administration: topical; once daily or once every 3 days; 28 days
Result: Triggered prominent hair coverage on day 10-11, showing superior hair coverage versus minoxidil at day 12, 14 and 16.
Achieved hair density equivalent to minoxidil, with both groups exhibiting higher hair density and distinctly enlarged hair diameter compared to the AGA model after daily topical use for 28 days.
Delivered hair regrowth potency comparable to minoxidil, with notably raised hair density and thickened hair diameter against the AGA model under triweekly administration.
Evoked no observable cutaneous irritation or histopathological lesions.
Animal Model: C57BL/6 (male, 6 weeks old)
Dosage: 1 mg/mL; 10 mg/mL; 100 mg/mL
Administration: topical
Result: Exhibited concentration-dependent skin retention, with 1 mg/mL formulation showing minimal retention, 10 mg/mL formulation presenting moderate retention, and 100 mg/mL formulation reaching the peak retention of 2900 ng/cm2.

化学信息

分子量 841.28
分子式 C39H44ClF3N10O6

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础